PURPOSE: Systemic administration of recombinant interleukin (IL)-2 is used to support the expansion and persistence of adoptively transferred antigen-specific CTLs in patients with cancer. However, IL-2 also expands regulatory T cells (Treg) that in turn impair the antitumor activity of CTLs. As recombinant IL-15 is approaching clinical applications, we assessed the effects of this cytokine on the proliferation and antitumor activity of CTLs in the presence of Tregs. We used the model of adoptive transfer of Epstein-Barr virus (EBV)-CTLs, as these cells induce responses in patients with EBV-associated Hodgkin lymphoma, and Tregs are frequently abundant in these patients. EXPERIMENTAL DESIGN: Tregs were isolated from the peripheral blood of healthy donors and patients with Hodgkin lymphoma or from Hodgkin lymphoma tumors and assessed for their ability to inhibit the proliferation and antitumor activity of EBV-CTLs in the presence of IL-15 or IL-2. Specific molecular pathways activated by IL-15 were also explored. RESULTS: We found that in the presence of Tregs, IL-15, but not IL-2, promoted the proliferation, effector function, and resistance to apoptosis of effectors T cells and EBV-CTLs. IL-15 did not reverse or block Tregs but instead preferentially supported the proliferation of CTLs and effector T cells as compared with Tregs. CONCLUSIONS: IL-15 selectively favors the survival, proliferation, and effector function of antigen-specific CTLs in the presence of Tregs, and thus IL-15, unlike IL-2, would have a significant impact in sustaining expansion and persistence of adoptively transferred CTLs in patients with cancer, including those infused with EBV-CTLs for treatment of EBV-associated malignancies.
PURPOSE: Systemic administration of recombinant interleukin (IL)-2 is used to support the expansion and persistence of adoptively transferred antigen-specific CTLs in patients with cancer. However, IL-2 also expands regulatory T cells (Treg) that in turn impair the antitumor activity of CTLs. As recombinant IL-15 is approaching clinical applications, we assessed the effects of this cytokine on the proliferation and antitumor activity of CTLs in the presence of Tregs. We used the model of adoptive transfer of Epstein-Barr virus (EBV)-CTLs, as these cells induce responses in patients with EBV-associated Hodgkin lymphoma, and Tregs are frequently abundant in these patients. EXPERIMENTAL DESIGN:Tregs were isolated from the peripheral blood of healthy donors and patients with Hodgkin lymphoma or from Hodgkin lymphoma tumors and assessed for their ability to inhibit the proliferation and antitumor activity of EBV-CTLs in the presence of IL-15 or IL-2. Specific molecular pathways activated by IL-15 were also explored. RESULTS: We found that in the presence of Tregs, IL-15, but not IL-2, promoted the proliferation, effector function, and resistance to apoptosis of effectors T cells and EBV-CTLs. IL-15 did not reverse or block Tregs but instead preferentially supported the proliferation of CTLs and effector T cells as compared with Tregs. CONCLUSIONS:IL-15 selectively favors the survival, proliferation, and effector function of antigen-specific CTLs in the presence of Tregs, and thus IL-15, unlike IL-2, would have a significant impact in sustaining expansion and persistence of adoptively transferred CTLs in patients with cancer, including those infused with EBV-CTLs for treatment of EBV-associated malignancies.
Authors: C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg Journal: Proc Natl Acad Sci U S A Date: 2002-11-11 Impact factor: 11.205
Authors: Padraic J Dunne; Jeffery M Faint; Nancy H Gudgeon; Jean M Fletcher; Fiona J Plunkett; Maria Vieira D Soares; Andrew D Hislop; Nicola E Annels; Alan B Rickinson; Mike Salmon; Arne N Akbar Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Thomas A Waldmann; Enrico Lugli; Mario Roederer; Liyanage P Perera; Jeremy V Smedley; Rhonda P Macallister; Carolyn K Goldman; Bonita R Bryant; Jean M Decker; Thomas A Fleisher; H Clifford Lane; Michael C Sneller; Roger J Kurlander; David E Kleiner; John M Pletcher; William D Figg; Jason L Yovandich; Stephen P Creekmore Journal: Blood Date: 2011-03-08 Impact factor: 22.113
Authors: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg Journal: Science Date: 2002-09-19 Impact factor: 47.728
Authors: Anna Maria Wolf; Dominik Wolf; Michael Steurer; Guenther Gastl; Eberhard Gunsilius; Beatrix Grubeck-Loebenstein Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: P Schlegel; T Feuchtinger; C Nitschke-Gérard; U J Eva Seidel; A-M Lang; C Kyzirakos; H-M Teltschik; M Ebinger; M Schumm; E Koscielniak; R Handgretinger; P Lang Journal: Bone Marrow Transplant Date: 2015-06 Impact factor: 5.483
Authors: Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti Journal: Blood Date: 2014-04-29 Impact factor: 22.113